Inflammasome Therapeutics
PrivateLast Round
Seed Round
Feb 27, 2026
Total Funding Raised
$3.22M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Inflammasome Therapeutics operates in Healthcare & Life Sciences and is based in Newton, Massachusetts. Its latest recorded funding round was a Grant round in May 2025.
Inflammasome Therapeutics is a biotechnology company that develops therapies for prevalent, degenerative diseases such as Alzheimer's, multiple sclerosis, and macular degeneration by preventing aberrant inflammasome activation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inflammasome Therapeutics Comparables
Compare Inflammasome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IFM Therapeutics | 90% | |
| NodThera | 88% | |
| Halia Therapeutics | 85% |
For institutional investors. Book with your work email.
Inflammasome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Feb 27, 2026 | ||||
| Grant | May 1, 2025 | ||||
| Seed | Dec 2, 2024 | ||||
| Seed Round | Aug 4, 2023 | ||||
| Grant | Aug 9, 2021 | ||||
Grant | Sep 16, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Inflammasome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boehringer Ingelheim | Strategic |
| Gates Foundation | Grant |
| Bill & Melinda Gates Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 57% QoQ from 7 to 11 employees.
- May 27, 2026
Grew 125% QoQ, from 4 to 9 employees.
For institutional investors. Book with your work email.
Inflammasome Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Inflammasome Therapeutics's valuation, stock price, and market status.
Is Inflammasome Therapeutics a public or private company?
Inflammasome Therapeutics is a private company.
What is the current stock price of Inflammasome Therapeutics?
Inflammasome Therapeutics is a private company, so its shares have no public market price. Caplight tracks Inflammasome Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Inflammasome Therapeutics worth (valuation)?
Valuation information for Inflammasome Therapeutics is not publicly available.
Can I buy Inflammasome Therapeutics stock?
Inflammasome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Inflammasome Therapeutics's last funding round?
Inflammasome Therapeutics's most recent funding round was Seed Round on February 27, 2026.
Who are the main investors in Inflammasome Therapeutics?
Key investors in Inflammasome Therapeutics include Boehringer Ingelheim, Bill & Melinda Gates Foundation.
Will Inflammasome Therapeutics IPO soon?
No public IPO plans have been announced for Inflammasome Therapeutics.
How can I track Inflammasome Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Inflammasome Therapeutics's shares on secondary markets.